

[illegible]

Applicants: Sharon Cohen-Vered, et al.  
Serial No.: 10/758,937  
Filed: January 14, 2004  
Exhibit A

[illegible]

Applicants: Sharon Cohen-Vered et al.  
Serial No. 10/758,397  
Filed: January 14, 2004  
**Exhibit A**


Group

[illegible][illegible][illegible]

**DATE CONSIDERED** 10/01/2006

\***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Applicants:** Sharon Cohen-Vered et al.  
**Serial No.:** 10/758,397  
**Filed:** January 14, 2004  
**Exhibit A**

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 68811-A/JPW/GJG/JBC		Serial No. 10/758,397	
 <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Applicants: Sharon Cohen-Vered et al.			
				Filing Date January 14, 2004		Group	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
MA	5 1 2 6 2 4 9	6/30/92	Becker, et al.;				
MA	5 1 3 4 1 2 7	7/28/92	Stella, et al.;				
MA	5 3 7 6 6 4 5	12/27/94	Stella, et al.;				
MA	6 6 1 3 5 3 6	9/2/03	Mozes, et al.;				
MA	10 7 5 8 5 7 2	1/14/04	Sharon Cohen-Vered, et al.				
<b>FOREIGN PATENT DOCUMENTS</b>							
	Document Number	Date	Country	Class	Subclass	Translation Yes No	
MA	EPO 0 4 9 5 0 4 9	7/22/92	EPO;				
MA	WO 9 6 3 0 0 5 7	10/3/96	PCT;				
MA	02 0 6 7 8 4 8	9/6/02	WO				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
MA	Audibert et al. (1981) Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide. <u>Nature</u> , 289:593-4;						
MA	Axelrod, O. and Mozes, E. (1986) Analysis of the biological functions and fine specificity of (T,G)-A--L specific T cell clones. <u>Immunobiology</u> , 172:99-109;						
MA	Bombardier C. et al. (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. <u>Arthritis Rheum.</u> , 35:630-40;						
MA	Conlon, P.J. (1983) A rapid biologic assay for the detection of interleukin 1. <u>J. Immunol.</u> , 134:1280-2;						
MA	Dayan M. et al. (2000) Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. <u>J. Clin. Immunol.</u> , 20(3):187-94						
MA	Dean G.S. et al. (2000) Cytokines and systemic lupus erythematosus. <u>Ann. Rheum. Dis.</u> , 59:243-51;						
MA	Eilat, E., et al. (2000) Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3- based peptides of pathogenic autoantibody. <u>J. Clin. Immunol.</u> , 20:268-78;						
MA	Eilat, E., et al. (2001) The mechanism by which a peptide based on complementarity determining region-1 of pathogenic anti-DNA antibody ameliorates experimental SLE. <u>Proc. Natl. Acad. Sci. U.S.A.</u> , 98: 1148-53;						
MA	Fricke, H. et al. (1991) Idiotype specific T-cell lines inducing experimental systemic lupus erythematosus in mice. <u>Immunology</u> , 73:421-7;						
MA	Fricke, H. et al. (1990) Induction of experimental systemic lupus erythematosus in mice by immunization with a monoclonal anti-La autoantibody. <u>Int. Immunol.</u> , 2:225-30;						
MA	Gearing, A.J.H. et al. (1994) Processing of tumor necrosis factor-alpha precursor by metalloproteinases. <u>Nature</u> , 370:555-7;						
MA	Gijbels, K. et al. (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. <u>J. Neuroimmunol.</u> , 41:29-34;						
MA	Goetzl, E.J. et al. (1996) Matrix metalloproteinases in immunity. <u>J. Immunol.</u> , 156:1-4;						
MA	Guedez, L. et al. (1996) The role of metalloproteinases and their inhibitors in hematological disorders. <u>Crit. Rev. Oncog.</u> , 7:205-25;						
EXAMINER /Maury Audet/		DATE CONSIDERED 10/01/2006					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Applicants: Sharon Cohen-Vered et al.  
 Serial No.: 10/758,397  
 Filed: January 14, 2004  
 Exhibit A



